Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Guardant Health Inc Market Cap
From what 7 stock analysts predict, the share price for Guardant Health Inc (GH) might increase by 97.97% in the next year. This is based on a 12-month average estimation for GH. Price targets go from $37.00 to $54.00. The majority of stock analysts believe GH is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Guardant Health Inc has a total of 7 Wall St Analyst ratings. There are 7 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Guardant Health Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| matthew sykes Goldman Sachs | Buy | $37.0 | maintained | Jan 29, 2024 |
| alexander nowak Craig-Hallum | Buy | $54.0 | maintained | Jan 9, 2024 |
| daniel arias Stifel Nicolaus | Buy | $45.0 | maintained | Jan 9, 2024 |
| kyle mikson cfa Canaccord Genuity | Buy | $50.0 | maintained | Jan 8, 2024 |
| puneet souda Leerink Partners | Buy | None | maintained | Jan 8, 2024 |
| derik de bruin Bank of America Securities | Buy | $38.0 | maintained | Jan 8, 2024 |
| mark massaro BTIG | Buy | $50.0 | maintained | Jan 1, 2024 |
| david westenberg Piper Sandler | Buy | $40.0 | rated | Dec 20, 2023 |
| doug schenkel Wolfe Research | Hold | None | initiatedcoverage | Dec 12, 2023 |
| andrew cooper Raymond James | Buy | $27.0 | upgraded | Nov 13, 2023 |
| tejas savant Morgan Stanley | Buy | $50.0 | maintained | Nov 7, 2023 |
| sung ji nam Scotiabank | Buy | $47.0 | reiterated | Nov 7, 2023 |
| daniel brennan TD Cowen | Buy | $44.0 | reiterated | Nov 6, 2023 |
| patrick b donnelly Citi | Buy | $50.0 | maintained | Oct 2, 2023 |
| eve burstein Bernstein | Buy | $34.0 | initiatedcoverage | Sep 28, 2023 |
| rachel vatnsdal J.P. Morgan | Buy | $60.0 | maintained | Aug 4, 2023 |
| dan leonard Credit Suisse | Buy | $55.0 | maintained | May 10, 2023 |
| max masucci Cowen & Co. | Buy | $53.0 | maintained | Feb 24, 2023 |
| julia qin J.P. Morgan | Buy | $65.0 | maintained | Feb 24, 2023 |
| mason carrico Stephens | Buy | $63.0 | reiterated | Feb 16, 2023 |
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360; Guardant360 LDT; Guardant360 CDx; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, a suite of advanced analytical technologies to enhance the performance and clinical utility of cancer tests. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. has a research collaboration agreement with the Parker Institute for Cancer Immunotherapy to study the correlation between molecular cancer biomarkers and patient response to immunotherapy treatment across various types of cancer. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
When did it IPO
2018
Staff Count
1,793
Country
United States
Sector/Industry
Healthcare/Diagnostics & Research
CEO
Dr. Helmy Eltoukhy Ph.D.
Market Cap
$2.77B
In 2023, GH generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that GH's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
FOXF-USD
$65.15
QDEL-USD
$41.76
PI-USD
$102.69
CALM-USD
$57.41
FHB-USD
$21.43
$26.12
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
